Coexistence of blaTEM, blaCTX, blaKPC, blaNDM, blaSIM e blaOXA-48 in polymicrobial bloodstream isolates from a patient with acute myeloid leukemia
DOI:
https://doi.org/10.33448/rsd-v10i5.14985Keywords:
Polymicrobial infection; β-Lactamase; Hematological malignancy; Carbapenemases; Bloodstream infection.Abstract
Background: Bloodstream infections are among the most frequent and serious complications in patients with haematological malignancies. Case presentation: A patient diagnosed with acute myeloid leukemia was admitted to the hospital for chemotherapy induction, developed several episodes of febrile neutropenia. Had bloodstream infection with at least four strains of Gram-negative bacteria, including Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumanii. The majority showed resistance to ampicillin, cefepime, ceftriaxone, ciprofloxacin and sulfamethoxazole/trimethoprim. blaTEM and blaSIM were detected in P. aeruginosa, blaTEM, blaCTX and blaOXA-48 in E. coli, blaCTX, blaKPC, blaNDM, blaSIM and blaOXA-48 in K. pneumoniae and blaOXA-48 in A. baumannii. Conclusions: The patient was treated with meropenem for 10 days, without progressing from fever episodes, evolved to death.
References
Agrawal, S. K., Gautam, H., Choudhary, A. H., Das, B. K., Kumar, L., & Kapil, A. (2019). Central line-associated bloodstream infections in cancer patients: An experience from a tertiary care cancer centre. Indian J Med Microbiol, 37(3):376-380.
Benanti, G. E., Brown, A. R. T., Shigle, T. L., Tarrand, J. J., Bhatti, M. M., McDaneld, P. M., et al. (2019). Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Escherichia coli in Patients with Hematologic Malignancy. Antimicrob Agents Chemother, 63(2):e01813-18.
Castañón, C., Fernández Moreno, A., Fernández Verdugo, A. M., Fernández, J., Martínez Ortega, C., Alaguero, M., et al. (2019). The Value of Adding Surveillance Cultures to Fluoroquinolone Prophylaxis in the Management of Multiresistant Gram Negative Bacterial Infections in Acute Myeloid Leukemia. J Clin Med, 8(11):1985.
Cattaneo, C., Di Blasi, R., Skert, C., Candoni, A., Martino, B., Di Renzo, N., et al; SEIFEM Group. (2018). Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria. Ann Hematol, 97(9):1717-1726.
Chong, Y., Yakushiji, H., Ito, Y., & Kamimura, T. (2010). Cefepime-resistantGram-negative bacteremia in febrile neutropenic patients with hematological malignancies. Int J InfectDis, 14(3):e171-5.
Dumont, Y., Bonzon, L., Michon, A. L., Carriere, C., Didelot, M. N., Laurens, C., et al. (2020). Epidemiology and microbiological features of anaerobic bacteremia in two French University hospitals. Anaerobe, 64:102207.
Islas-Muñoz, B., Volkow-Fernández, P., Ibanes-Gutiérrez, C., Villamar-Ramírez, A., Vilar-Compte, D., VCornejo-Juárez, P. (2018). Bloodstream infections in cancer patients. Risk factors associated with mortality. Int J InfectDis, 1:59-64.
Khan, A., Shropshire, W. C., Hanson, B., Dinh, A. Q., Wanger, A., et al. (2020). Simultaneous Infection with Enterobacteriaceae and Pseudomonas aeruginosa Harboring Multiple Carbapenemases in a Returning Traveler Colonized with Candida auris. Antimicrob Agents Chemother, 27;64(2):e01466-19.
Lubwama, M., Phipps, W., Najjuka, C. F., Kajumbula, H., Ddungu, H., Kambugu, J. B., et al. Bacteremia in febrile cancer patients in Uganda. BMC Res Notes. 2019;12(1):464. 10.1186/s13104-019-4520-9
Mert, D., Ceken, S., Iskender, G., Iskender, D., Merdin, A., Duygu, F., et al. (2019). Epidemiology and mortality in bacterial bloodstream infections in patients with hematologic malignancies. J Infect Dev Ctries, 13(8):727-735.
Mimura, W., Fukuda, H., & Akazawa, M. (2020). Antimicrobial utilization and antimicrobial resistance in patients with haematological malignancies in Japan: a multi-centre cross-sectional study. Ann Clin Microbiol Antimicrob, 19(1):7.
Nham, E., Huh, K., Cho, S. Y., Chung, D. R., Peck, K. R., Lee, N. Y., & Kang, C. I. (2020). Characteristics and Clinical Outcomes of Extended-Spectrum beta-lactamase-producing Klebsiella pneumoniae Bacteremia in Cancer Patients. Infect Chemother, 52(1):59-69.
Pagano, L., Caira, M., Trecarichi, E. M., Spanu, T., Di Blasi, R., Sica, S., et al. (2014). Carbapenemase-producing Klebsiella pneumonia and hematologic malignancies. Emerg Infect Dis, 20(7):1235-6.
Rosa, R. G., & Goldani, L. Z. (2014). Factors associated with hospital length of stay among cancer patients with febrile neutropenia. PLoS One, 6;9(10):e108969.
Satlin, M. J., Calfee, D. P., Chen, L., Fauntleroy, K. A., Wilson, S. J., Jenkins, S. G., et al. (2013). Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leuk Lymphoma, 54(4):799-806.
Shargian-Alon, L., Gafter-Gvili, A., Ben-Zvi, H., Wolach, O., Yeshurun, M., Raanani, P., & Yahav, D. (2019). Risk factors for mortality due to Acinetobacter baumannii bacteremia in patients with hematological malignancies - a retrospective study. Leuk Lymphoma, 60(11):2787-2792.
Tang, Y., Wu, X., Cheng, Q., & Li, X. (2020). Inappropriate initial antimicrobial therapy for hematological malignancies patients with Gram-negative bloodstream infections. Infection, 48(1):109-116.
Tofas, P., Samarkos, M., Piperaki, E. T., Kosmidis, C., Triantafyllopoulou, I. D., Kotsopoulou, M., et al. (2017). Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: risk factors, treatment and outcome. Diagn Microbiol Infect Dis, 88(4):335-341.
Wakisaka, K., Tani, S., Ishibashi, K., Nukui, K., & Nagao, M. (2015). Results of a post-marketing surveillance of meropenem for febrile neutropenia. Jpn J Antibiot, 68(4):205-24.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Cynthia Regina Pedrosa Soares; Vera Magalhães; Paulo Sérgio Ramos de Araújo
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
